Basyoni Maha M A, Fouad Shawky A, Amer Marwa F, Amer Ahmed Fathy, Ismail Dalia Ibrahim
Medical Parasitology Department, Faculty of Medicine, Cairo University, Egypt.
Internal Medicine Department, Faculty of Medicine, Cairo University, Egypt.
Korean J Parasitol. 2018 Apr;56(2):105-112. doi: 10.3347/kjp.2018.56.2.105. Epub 2018 Apr 30.
is an enteric Straminopile in tropical, subtropical and developing countries. Metronidazole has been a chemotheraputic for blastocystosis. Failures in its regimens were reported and necessitate new studies searching for alternative therapeutic agents. Aim of current study is to investigate potential effects of Atorvastatin (AVA) compared to the conventional chemotherapeutic MTZ in experimentally -infected mice. Anti- efficacy of AVA was evaluated parasitologically, histopathologically and by transmission electron microscopy using MTZ (10 mg/kg) as a control. Therapeutic efficacy of AVA was apparently dose-dependent. Regimens of AVA (20 and 40 mg/kg) proved effective against infections with high reduction in shedding (93.4-97.9%) compared to MTZ (79.3%). The highest reductions (98.1% and 99.4%) were recorded in groups of combination treatments AVA 20-40 mg/kg and MTZ 10 mg/kg. was nearly eradicated by the 20th day post infection. Genotype analysis revealed that genotype I was most susceptible, genotype III was less. Histopathologic and ultrastructural studies revealed apoptotic changes in and significant improvement of intestinal histopathological changes more remarkable in combinational therapy groups. Thus, the present study offers AVA as a potential candidate for therapy combined with MTZ.
是热带、亚热带和发展中国家的一种肠道茸鞭生物。甲硝唑一直是治疗芽囊原虫病的化疗药物。有报道称其治疗方案存在失败情况，因此需要开展新的研究来寻找替代治疗药物。本研究的目的是在实验感染小鼠中，将阿托伐他汀（AVA）与传统化疗药物甲硝唑（MTZ）进行比较，研究其潜在效果。以MTZ（10mg/kg）作为对照，通过寄生虫学、组织病理学以及透射电子显微镜观察来评估AVA的抗虫效果。AVA的治疗效果明显呈剂量依赖性。与MTZ（79.3%）相比，AVA（20和40mg/kg）方案对感染有效，虫体排出量大幅减少（93.4 - 97.9%）。AVA 20 - 40mg/kg与MTZ 10mg/kg联合治疗组的虫体减少率最高（分别为98.1%和99.4%）。感染后第20天虫体几乎被根除。基因型分析显示，I型基因型最敏感，III型较不敏感。组织病理学和超微结构研究显示，芽囊原虫出现凋亡变化，联合治疗组肠道组织病理学变化有显著改善。因此，本研究表明AVA有可能成为与MTZ联合治疗芽囊原虫病的候选药物。
